Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. (PACB) on September 12, 2020. The filing primarily addresses the appointment of a new Chief Financial Officer and the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes rather than financial performance data.
Material Changes
The material change reported is the appointment of Susan G. Kim as Chief Financial Officer, effective September 28, 2020. She replaces Ben Gong, who served as interim CFO since August 8, 2020.
Management Commentary and Compensation Details
Ms. Kim's compensation package includes the following terms:
- Base Salary: $415,000 annually.
- Signing Bonus: $75,000 one-time payment, subject to pro rata repayment if employment ends before 12 months.
- Target Bonus: 50% of base salary, contingent on performance goals.
- Stock Options: 400,000 shares under the 2020 Equity Incentive Plan. Vesting schedule: 25% on the 1-year anniversary of the effective date, with the remainder vesting monthly (1/48th per month).
- Restricted Stock Units (RSUs): 150,000 shares. Vesting schedule: 25% on each anniversary of the grant date.
- Severance and Change in Control: Eligible for 12 months of base salary and COBRA coverage upon termination without cause or resignation for good reason. In the event of a change in control within 12 months of termination, 100% of unvested equity awards accelerate, with performance goals deemed achieved at 100% of target.
Investor Verification Checklist
- Verify the commencement date of Ms. Kim's employment (September 28, 2020) and the transition from the interim CFO.
- Review the specific performance goals tied to the annual bonus and RSU vesting, as these are not detailed in this filing.
- Confirm the fair market value per share on the grant date for the 400,000 stock options to assess dilution impact.
- Monitor future filings for the execution of the change in control and severance agreement referenced in the offer letter.